Basis of Presentation and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2014

Basis of Presentation and Summary of Significant Accounting Policies

Analysis of U.S. Feraheme product sales allowances and accruals

An analysis of our U.S. Feraheme product sales allowances and accruals for the three and six months ended June 30, 2014 and 2013 is as follows (in thousands):

	Three Months Ended June 30,
	2014			2013
Provision for U.S. Feraheme product sales allowances and accruals
Discounts and chargebacks	$	13,415		$	9,227
Government and other rebates	3,952			2,732
Returns	146			239
Total provision for U.S. Feraheme product sales allowances and accruals	17,513			12,198
Total gross U.S. Feraheme product sales	$	39,738		$	29,654
Total provision for U.S. Feraheme product sales allowances and accruals as a percent of total gross U.S. Feraheme product sales	44		%	41		%

	Six Months Ended June 30,
	2014			2013
Provision for U.S. Feraheme product sales allowances and accruals
Discounts and chargebacks	$	23,948		$	16,720
Government and other rebates	7,139			5,119
Returns	372			432
Total provision for U.S. Feraheme product sales allowances and accruals	31,459			22,271
Total gross U.S. Feraheme product sales	$	71,059		$	55,305
Total provision for U.S. Feraheme product sales allowances and accruals as a percent of total gross U.S. Feraheme product sales	44		%	40		%

Schedule of customers representing 10% or more of revenues

	Six Months Ended June 30,
	2014		2013
AmerisourceBergen Drug Corporation	38	%	43	%
McKesson Corporation	25	%	23	%
Cardinal Health, Inc.	17	%	15	%
Takeda Pharmaceuticals Company Limited	10	%	11	%